Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

NCT01238029 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped new methods of treatment, no more patients appilicable for study

Conditions

Metastatic Breast Cancer
HER2 Positive
First or Second Line Therapy
Failure or Contraindication of Trastuzumab Therapy

Interventions

DRUG: Lapatinib and Capecitabine and Vinorelbine

Sponsor

Sponsor GmbH

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]